Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

AK Bose, MM Mocanu, RD Carr, CL Brand… - Diabetes, 2005 - Am Diabetes Assoc
AK Bose, MM Mocanu, RD Carr, CL Brand, DM Yellon
Diabetes, 2005Am Diabetes Assoc
Glucagon-like peptide 1 (GLP-1), a gut incretin hormone that stimulates insulin secretion,
also activates antiapoptotic signaling pathways such as phosphoinositide 3-kinase and
mitogen-activated protein kinase in pancreatic and insulinoma cells. Since these kinases
have been shown to protect against myocardial injury, we hypothesized that GLP-1 could
directly protect the heart against such injury via these prosurvival signaling pathways. Both
isolated perfused rat heart and whole animal models of ischemia/reperfusion were used …
Glucagon-like peptide 1 (GLP-1), a gut incretin hormone that stimulates insulin secretion, also activates antiapoptotic signaling pathways such as phosphoinositide 3-kinase and mitogen-activated protein kinase in pancreatic and insulinoma cells. Since these kinases have been shown to protect against myocardial injury, we hypothesized that GLP-1 could directly protect the heart against such injury via these prosurvival signaling pathways. Both isolated perfused rat heart and whole animal models of ischemia/reperfusion were used, with infarct size measured as the end point of injury. In both studies, GLP-1 added before ischemia demonstrated a significant reduction in infarction compared with the valine pyrrolidide (an inhibitor of its breakdown) or saline groups. This protection was abolished in the in vitro hearts by the GLP-1 receptor antagonist exendin (9-39), the cAMP inhibitor Rp-cAMP, the PI3kinase inhibitor LY294002, and the p42/44 mitogen-activated protein kinase inhibitor UO126. Western blot analysis demonstrated the phosphorylation of the proapoptotic peptide BAD in the GLP-1–treated groups. We show for the first time that GLP-1 protects against myocardial infarction in the isolated and intact rat heart. This protection appears to involve activating multiple prosurvival kinases. This finding may represent a new therapeutic potential for this class of drug currently undergoing clinical trials in the treatment of type 2 diabetes.
Am Diabetes Assoc